07 May 2021: Clinical Research
Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis
Anthony Matta 123ABCDEF , Vanina Bongard 12ABCDEF , Frédéric Bouisset 12ABCDEF , Dorota Taraszkiewicz 12ABCDEF , Jean-Pierre Rabès 4BDEF , Jean Ferrières 12ABCDEFG*DOI: 10.12659/MSM.928784
Med Sci Monit 2021; 27:e928784
Table 3 A comparison of the responder rate between the 3 groups.
| Whole population (n=123) | PCSK9i (n=83) | PCSK9i+ezetimibe (n=12) | PCSK9i+statin and ezetimibe (n=28) | |
|---|---|---|---|---|
| Responders, n (%) | 61 (49.6%) | 32 (38.6%) | 7 (58.3%) | 22 (78.6%) |
| Odds ratio | 2.20 | 6 | ||
| 95% Confidence interval | (0.6–8.1) | (2–17.6) | ||
| P value | 0.24 | 0.001 | ||
| PCSK9i – proprotein convertase subtilisin/kexin type 9 inhibitors. | ||||